Clinical use
Diagnosis and subsequent monitoring of a diverse group of neoplasms that arise from the endocrine and nervous systems. The large number of potential serum tumour markers associated with tumours of this type necessitates a panel of markers being assembled resulting in the screens listed below. Patient symptoms may aid the clinician in selecting the appropriate screen.
Background
Endocrine Diarrhoea Screen (EDS) – Measures those peptides that may be the cause of endocrine diarrhoea and includes Vasoactive Intestinal Peptide which increases secretions from the intestines, Neurokinin A which contracts smooth muscle and Pancreatic Polypeptide which affects gastro-intestinal secretions and increases gut motility.
Tests will be done in two groups:Group 1 – Chromogranin A, Neurokinin A, Gastrin and Pancreatic Polypeptide
Group 2 – Pancreastatin and Vasoactive Intestinal Peptide.
Reference ranges
Please see report
Patient preparation
For suspected gastrinomas, patient off proton pump inhibitors for 2 to 3 days, then request Gastrin, Chromogranin A and Pancreatic Polypeptide.
Specimen requirements
2 x EDTA Tubes (full)
Turnaround time
4 weeks
Time limit for retrospective requesting
N/A
Additional Information
Referred test
Referred test
Location
SAS Laboratory
